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Desmoid-type fibromatosis is a rare and locally aggressive monoclonal, fibroblastic proliferation characterized by a variable and
often unpredictable clinical course. Currently, there is no established or evidence-based treatment approach available for this
disease. Therefore, in 2015 the European Desmoid Working Group published a position paper giving recommendations on the
treatment of this intriguing disease. Here, we present an update of this consensus approach based on professionals’ AND
patients’ expertise following a round table meeting bringing together sarcoma experts from the European Organization for
Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group with patients and patient advocates from Sarcoma
PAtients EuroNet. In this paper, we focus on new findings regarding the prognostic value of mutational analysis in desmoid-
type fibromatosis patients and new systemic treatment options.
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Introduction
General issues and epidemiology
Desmoid-type fibromatosis (DF) is a rare monoclonal, fibroblas-
tic proliferation characterized by a variable and often unpredict-
able clinical course. In the International Classification of
Diseases, it is classified as D48.1. According to the World Health
Organization (WHO), DF is a ‘clonal fibroblastic proliferation
that arises in the deep soft tissues and is characterized by infiltra-
tive growth and a tendency toward local recurrence but an inabil-
ity to metastasize’, even though they may be multifocal in the
same limb or body part [1]. DF is a distinct rare entity (incidence
five to six cases per 1 million of the population per annum [2])
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with a peak age of 30–40 years [2, 3]. Approximately 5%–10%
arises in the context of familial adenomatous polyposis (FAP);
however, this will not be discussed in this paper.
Level of evidence
Considering the variable clinical presentations, anatomic loca-
tions and biologic behaviors, a highly individualized treatment
approach by expert teams is required. Due to the rarity of the dis-
ease, the level of evidence available for common types of cancer is
unlikely ever to be available for DF. There is no published phase
III randomized clinical study; only few phase II trials and mainly
retrospective analyses are available. As for rare cancers and dis-
eases, a higher level of uncertainty needs to be accepted in DF
both for regulatory and for clinical decision-making.
Methodology
This position paper adheres to the European Organization for
Research and Treatment of Cancer (EORTC) Policy 19 on
‘Guidelines, Expert Opinions, and the use of EORTC Results in
Promotional Material on Cancer Care’ (http://www.eortc.org/
app/uploads//03/POL019.pdf) and has formal EORTC Board ap-
proval. The level of evidence available and the grade of recom-
mendation are classified according to the ESMO guidelines. In
2015, the European Desmoid Working Group published a first
position paper giving recommendations on the treatment of DF
[4]. Here, we present an update of this consensus approach based
on professionals’ and patients’ expertise following a 2nd Round
Table Meeting on 23 February 2017 bringing together soft tissue
tumor experts from the EORTC Soft Tissue and Bone Sarcoma
Group (STBSG) with patients and patient advocates from
Sarcoma PAtients EuroNet (SPAEN). In this paper, we focus on
new findings regarding the prognostic value of the mutational
analysis in DF patients and an update on systemic treatment
options.
Pathology/molecular biology
Biopsy
The histopathologic confirmation of DF is mandatory before ini-
tiating treatment. A diagnosis of DF can be readily established on
core biopsies using 14G or 16G needles, while neither incisional
nor excisional biopsy is recommended as the initial diagnostic
modality. According to the rarity of DF and manifold potential
histologic mimics, some reference centers have reported rates of
misdiagnosed cases as high as 30%–40% during initial work-up
[2, 5]. Noteworthy, nuclear accumulation of b-catenin on immu-
nostaining has been observed in non-DF soft tissue neoplasms as
well, while activating mutations in CTNNB1 (the gene encoding
b-catenin) were confined to DF in the differential diagnostic set-
ting compared with other soft tissue neoplasms [6]. Accordingly,
we strongly recommend that DF diagnosis should be confirmed
by an expert soft tissue pathologist and ideally mutational ana-
lysis should be strongly considered in diagnostically equivocal or
uncertain cases [7].
Resection specimen
Although the macroscopic appearance of DF is typically nodular
with a bulky mass appearance (Figure 1A), tentacle-like spicu-
lated extensions with infiltrative growth are regularly found
(Figure 1B). Accordingly, resection margins should be evaluated
carefully by extensive sampling [8]. Intra-operative frozen section
evaluation of resection margins is not regularly recommended.
The macroscopic and microscopic aspects of DF have been
described in detail in the first consensus paper [4].
Molecular biology
Approximately 85%–90% of DF harbors mutations in the
b-catenin gene, leading to nuclear accumulation of b-catenin
Figure 1. (A) Macroscopic picture of DF. Note ﬁnger-like extensions
(arrow) into muscle (M). (B) Microscopic picture of DF arising from deep
fascia (F). Note the inﬁltrative growth into skeletal muscle (arrows). (C)
Screen-shot of next-generation sequencing analysis of b-catenin T41A
mutation, with missense mutation A>G in only a subset of the reads.
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protein (Figure 2). b-Catenin mutations and APC mutations ap-
pear to be mutually exclusive in DF, thus, detection of a somatic
b-catenin mutation may help to exclude a syndromal condition
[9]. Vice versa, b-catenin wildtype status in DF should raise sus-
picion for FAP, with more extensive diagnostic clinical work-up
(e.g. colonoscopy). Mutation analysis of b-catenin has been pro-
posed as a specific diagnostic tool for establishing DF diagnosis,
particularly in challenging or diagnostically ambiguous cases
[10]. In some cases (e.g. with low tumor cell content), applica-
tion of next-generation sequencing is slightly more sensitive
compared with classical Sanger sequencing as it detects cases
with low mutational allelic fractions, with reported frequencies
of 93%–95% [11] (Figure 1C). Mutations of b-catenin in DF
cluster in the N-terminal region comprising codons 32–45
encoded by exon 3. Although T41A and S45F are by far the most
common mutations in DF accounting for roughly 50% and
25%, respectively, S45P is the third most common mutation at
around 9% and very rare missense mutations and deletions af-
fecting codons 32–49 have been observed as well [11]. Thus, all
codons 32–49 should be included in a mutation analysis, and
the sensitivity of the assay should be adequate to the estimated
tumor cell content.
Prognostic relevance of b-catenin mutations
A significant correlation between b-catenin S45F mutation and
an increased risk of recurrence after resection was observed in
four independent studies [12–15], and S45F mutations were
overrepresented in a clinical trial of DF patients with RECIST
progressive disease [16]. Notably, in that trial DF with S45F mu-
tation showed the highest progression arrest rate of 85% when
treated with 2 years of imatinib 800 mg/day, compared with only
43% progression arrest rate in DF with b-catenin wild-type status.
Taken together, these findings strongly encourage mutation ana-
lysis of b-catenin in DF to identify patients with a probably more
aggressive course, and to estimate response to imatinib therapy.
However, to date there are no prospective data on the prognostic
value of b-catenin (CTNNB1) mutation status at the time of first
diagnosis, but studies addressing this point are ongoing.
Imaging
Diagnosis
MRI is the mainstay of imaging in DF and can be used for diagno-
sis, local staging and follow-up [17, 18]. Once the diagnosis is es-
tablished, follow-up MRI is often carried out without
intravenous contrast, minimizing risk for the patient [19], and
the key diagnostic feature of hypointense bands is identifiable on
T2W images [20]. An association has been shown between lesion
growth and high T2W signal intensity [21], but prediction of be-
havior has been challenging [22]. An increase in collagen depos-
ition and decrease in extracellular space results in a decrease in
T2W signal intensity [23, 24]; also in lesions responding to treat-
ment [25, 26]. Lesions are frequently intermuscular, infiltrating
along facial planes [27, 28] and can be multifocal although usu-
ally in the same body part.
Follow-up and response assessment
The dimension-based RECIST is currently employed within clin-
ical trials [29]. The lack of radiation exposure makes targeted MRI
ideal for follow-up. MRI surveillance has been used to assess re-
sponse to treatment with a decrease in T2W signal and lesion size
[30] and FDG PET/CT may give an early indication of response in
patients treated with imatinib [31]. However, future applications
should be selected so that the benefit of imaging outweighs the risk
of radiation exposure particularly where multiple assessments for
non-malignant pathology are carried out in young patients.
Indication for treatment
Immediate surgery is no more the standard treatment of DF.
Retrospective series have shown progression-free survival rates of
50% at 5 years for asymptomatic patients managed with a front-
line conservative ‘watchful waiting’ approach [32–35]. These pa-
tients remained under close observation, such that no patient was
lost to follow-up and treatment plans could be altered if tumors
progressed. No significant prognostic factors identified patients
who do not need treatment from those who need active therapy
at diagnosis. This is further complicated by the fact that tumor
growth but also tumor site and size may be decision factors, as
same sized tumors may remain asymptomatic in some sites and
be life-threatening in others. Spontaneous regressions are
observed in as many as 20%–30% of cases (Figure 3) [36]. There
may be sites where regression is more common (i.e. abdominal
wall [37]), however, regression has been observed at all sites [38].
It is reasonable to consider watchful waiting as an initial step
when asymptomatic tumors are located at critical sites (i.e. mes-
entery) before undertaking subsequent treatments (IV, B); the
same is valid for intra-abdominal DF [39].
Surgery
Before 2000, the management of sporadic DF mirrored that of
soft tissue sarcoma with surgery as the standard of care. Multiple
retrospective single institution case series have reported local
control rates after complete surgical resection to be 80% at
Figure 2. Immunohistochemistry of a DF with characteristic b-cate-
nin staining.
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5 years. Tumor location was found to be a risk factor for recur-
rence, with abdominal wall DF portending a better prognosis, fol-
lowed by intra-abdominal DF, trunk DF and extremity DF
portending a worse outcome. Recurrent disease was found to be a
risk factor for further recurrence. Surgical margins, however, do
not consistently correlate with recurrence [40], while b-catenin
mutational status does (Tables 1 and 2). A recently published
nomogram incorporates tumor site, size and patient age in esti-
mating the risk of local recurrence; however, surgical margins are
not included [41]. This observation led to a reassessment of the
overall management, and preservation of function became a pri-
ority. Therefore, many investigators proposed to further limit
morbidity by considering an initial observation period in all
patients, especially when surgery would involve loss of function
[32–35]. When the surveillance approach fails, surgery is still a
valid option (IV, A). In case of progression medical treatment or
radiotherapy should also be considered factoring localization and
age. When carried out, surgical resection should be aimed at ob-
taining microscopic negative margins, although function preser-
vation—especially for tumors located in the extremities and
girdles—should always be an important goal and other alterna-
tives, including radiation therapy, can be considered when ap-
propriate. Furthermore, a large sporadic mesenteric/
retroperitoneal DF may be treated by surgical resection due to
tumor size and possible related symptoms.
Therefore, watchful waiting is a reasonable approach to min-
imize overtreatment and unnecessary morbidity in a subset of pa-
tients (IV, B). Prospective observational studies are presently
underway to validate these results and possibly shed more light
on the biologic background of this intriguing disease
(NCT01801176, NCT02547831 and NTR4714) [42].
Spontaneous regressions of DF may have to do with the immuno-
logic environment of the host. Studies are ongoing to better
understand the role of immunity in the course of the disease.
However no studies with immunomodulators have been run or
planned so far. In distinct clinical situations such as complica-
tions (occlusion, perforation etc. with or without systematic re-
section of all the mass) or major cosmetic issues patients can be
operated upfront. On the other hand, pain and pregnancy should
not be considered per se as unequivocal indication for surgery. As
a matter of fact, while the progression risk during pregnancy is as
high as 40%–50%, this can be safely managed. An active treat-
ment is required in less than half of the patients and only a minor-
ity requires an operation. Moreover, DF does not increase the
obstetric risk and it should not be a contraindication to future
pregnancy. There are presently no data to recommend a specific
Table 1. Prognostic factors in DF: surgical margins and clinical outcome in sporadic DF
Period No. of
patient
Primary/
Recurrent
Median
FU (months)
5-year
DFS
5-year
DFS (M1/M2)
10-year
DFS
10-year
DFS (M1/M2)
P
Merchant et al. [76] 1982–1997 105 All primary 49 75% 76%/74% N/R N/R 0.51
Gronchi et al. [77] 1966–2001 203 128 Primary 130 81% 79%/82% 76% 74%/77% 0.5
75 Recurrence 153 59% 47%/65% 59% 47%/65% 0.19
Lev et al. [78] 1995–2005 189 140/49 68 80% 80%/80% 79% 79%/79%
Bonvalot et al. [33] 1988–2003 89 All primary 76 44% 35%/60% N/R N/R 0.09
Huang et al. [79] 1987–2007 151 113 Primary 102 87% 64%/92% 85% 64%/92% 0.0001
38 Recurrence 102 56% 35%/71% 56% 35%/71% 0.09
Salas et al. [40] 1965–2008 370 All primary 53 60% 60%/60% 50% 50%/50%
Mullen et al. [80] 1970–2009 177 133/44 40 61% 52%/82% 60% 52%/77% 0.008
Crago et al. [41] 1982–2011 495 382/113 60 69% 69%/69% 65% 65%/65%
Van Broekhoven
et al. [81]
1989–2011 132 All primary 38 82.4% 80%/85% N/R N/R 0.7
Cates et al. [8] 1983–2011 92 All primary 38 N/R 58%/87% N/R 50%/87% 0.02
Background in light blue: studies showing an association of quality of surgical margins and risk of local relapse. Background in dark blue: studies NOT
showing any association of quality of surgical margins and risk of local relapse.
Deﬁnition of resection margins is not consistent in all studies: deﬁnition of positive/negative varies from<1mm/1mm to 0mm/>0mm. The sampling
protocol of the surgical specimen (number of sections to evaluate surgical margins) is not reported in any of the series, but one where the critical number
of sections looked to be 7 [8].
Baseline
A
B
Baseline
5-yr after W&S
8-yr after W&S
Figure 3. Examples of spontaneous regression of DF at different
sites. (A) Intra-abdominal DF. (B) Scapular girdle DF.
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delay between the onset of a watchful waiting approach and preg-
nancy, although it is reasonable to wait at least a year or two in
order to understand whether the disease is stable or progressing
and no active therapies are in fact needed [43].
Isolated limb perfusion and cryoablation
In patients with progressive, locally advanced extremity DF,
where resection would result in important functional sacrifice,
isolated limb perfusion (ILP) with tumor necrosis factor alpha
and melphalan seems to be a very effective treatment option [44,
45]. With a median follow-up of 7 years, 90% of 25 patients had
disease control; of these, 40% developed disease progression
after a median of 2 years [45]. This modality can be followed by
substantial side effects, although the use of low dose TNF (1 mg)
and moderate temperature (never above 39 C) have made this
procedure safer than in the past. Therefore, it can be considered
an option even in this condition, as long as it is delivered as
above.
Cryoablation has been reported in case series to be an effective
alternative treatment of small and moderately sized extra-
abdominal DF. It is of limited use in patients with larger tumors
that can only be partially treated due to the involvement of vital
structures. Continuing research is necessary [46, 47] and a non-
randomized phase II study in France is ongoing (NCT02476305).
Of note, both approaches are not available in every center and
do require particular expertise.
Radiotherapy
There is no change regarding previously made recommendations
for asymptomatic patients, operable symptomatic and/or pro-
gressive patients and inoperable symptomatic and/or progressive
patients [48–51]. Radiotherapy to a dose of 56 Gy in 28 once-
daily fractions of 2 Gy has been shown to provide adequate local
control in the majority of progressive patients (III, A) [50].
Radiotherapy techniques
Regardless of the indication, radiotherapy should be delivered by the
best available techniques such as Intensity Modulated Radiotherapy
(IMRT) and Image Guided Radiotherapy (IGRT). Coregistration
with (contrast enhanced) MRI sequences, preferably in treatment
position, is imperative. Whether the chosen dose should be applied
by conventional, linear accelerator based photons or proton beam
therapy is an issue of debate and future research [52].
Given the proximity of radiation sensitive organs in the ab-
dominal cavity, radiotherapy to the abdominal wall per se is not
contraindicated, but should be regarded as a challenge and only
to be applied with great caution applying modern techniques
such as IMRT and IGRT, taking respiratory motion into account.
Combining radiotherapy and surgery
Post-operative radiation has not demonstrated a conclusive
benefit after first surgery regardless of resection margins.
However, adjuvant radiotherapy may reduce the risk of recur-
rence after incomplete surgical resection, particularly in patients
with recurrent tumors [53]; comparable conclusions have been
drawn by different meta-analyses [54–56]. Therefore, careful
consideration on the morbidity of salvage surgery in case of local
recurrence after surgery only compared with late morbidity of ad-
juvant radiotherapy is mandatory in every individual case.
Medical therapy
Systemic treatment options comprise antihormonal therapies
with no histologic support from the presence of ER-/PR-positiv-
ity but from availability and reimbursement, non-steroidal anti-
inflammatory drugs (NSAIDs), low-dose chemotherapy, tyrosine
kinase inhibitors, and full-dose chemotherapy including liposo-
mal doxorubicin [57, 58]. Recently, new treatment strategies
have emerged such as targeting the Notch signaling pathway [59].
Table 2. Prognostic factors in DF: b-catenin (CTNNB1) mutational status and clinical outcome in sporadic DF
Period No. of
patients
Primary/
recurrent
Median FU
(months)
5-year
DFS
5-year DFS WT/
T41A/S45F
10-year
DFS
10-year
DFS (M1/M2)
P
Lazar et al. [12] 1985–2005 138 89/39 N/R 49% 65%/57%/23% N/R N/R 0.0001
Doˆmont et al. [13] 1987–2007 101 57/44 62 49% 75%/43%a N/R N/R 0.02
Colombo et al. [14] 1998–2011 179 All primary 50 70% 91%/66%/45% N/R N/R 0.05
Mullen et al. [82] 1984–2009 115 95/20 N/R 71% 74%/55%/60% N/R N/R 0.28
Van Broekhoven
et al. [15]
1989–2013 101 All primary 41 77% 87%/88%/46% N/R N/R 0.001
Background in light blue: studies NOT showing any association of ß-catenin mutational status and risk of local relapse. Background in dark blue: Studies
showing an association of b-catenin mutational status and risk of local relapse.
Comments: Of note, S45F mutated tumors are more common in extremity DF in all series. In Colombo et al. [14], the largest series so far, the administration
of RT seemed to offset the negative prognostic impact of S45F.
aAll mutated tumors were considered together. When the 3 different mutated tumors were considered separately, only a trend for a worse outcome of
S45F could be observed.
FU, follow-up; DFS, disease-free survival; Mþ, positive margins; M, negative margins; N/R, not reported.
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Anti-hormonal agents such as tamoxifen may be used—alone
[60] or in combination with NSAIDs [61]—as first medical
treatment, mainly because of their limited toxicity, rare adverse
events and low costs [62] (III, B). However, response rates have
been found to be low and no clear relationship between symp-
tom changes, size or MRI signal changes could be demonstrated
[63]. Therefore, a general recommendation for its use cannot be
given.
When the relevant issue is critical anatomic site, in the case of
hormonal therapy failure or for aggressively growing, symptom-
atic or even life-threatening DF, chemotherapy is advisable
using either a ‘low dose’ regimen with methotrexate and/or vin-
blastine/vinorelbine [64–67] (III, B). Conventional dose
chemotherapy using anthracycline-based regimes is another op-
tion if more rapid response is desired (e.g. for intra-abdominal
or head and neck DF) [65]. It is usually administered for six to
eight cycles, i.e. until the maximum tolerated dose of anthracy-
cline is reached; however, using lower dosages and more cycles
may be possible. Pegylated liposomal doxorubicin has been re-
ported in uncontrolled patient series to have significant activity
with acceptable toxicity and, importantly in this young patient
population, less cardiac toxicity than conventional doxorubicin
[68, 69].
There is prospective, uncontrolled evidence for the activity of
the tyrosine kinase inhibitor (TKI) imatinib in progressive DF
patients with high rates of stabilization (60%–80%) despite rather
low response rates (6%–16%) with a well-known toxicity profile
[70–72] (III, B). In the most recent publication of the German
Interdisciplinary Sarcoma Group (GISG) imatinib induced sus-
tained progression arrest in RECIST progressive DF patients. In
addition, nilotinib had the potential to stabilize DF growth even
after imatinib failure [73]. In a retrospective cohort, the use of sor-
afenib revealed a higher response rate with 25% and a disease sta-
bilization rate of 70% [25]; however, the updated analysis revealed
a response rate of 18% which is in the same range as described for
imatinib [74]; no prospective data are available yet. Currently, sor-
afenib is being evaluated in a phase III, placebo-controlled setting
(NCT02066181), presently closed to patient entry. In a cohort of
eight patients treated with pazopanib, partial responses were re-
ported in three and disease stabilization in five patients without
any radiologic disease progression [75].
Notch signaling is a new systemic treatment strategy. Gamma-
secretase cleaves intracellular Notch resulting in Notch signaling.
PF-03084014 is an oral, reversible gamma-secretase inhibitor.
A phase II study of PF-03084014 has been conducted in 17 DF pa-
tients (in contrast to 150 patients prospectively treated with
imatinib) who had progressed following at least one line of ther-
apy. Five partial responses (29%) were shown and 12 out of the
17 patients demonstrated stable disease; there were no disease
progressions [59]. Unfortunately, the drug is not available at pre-
sent and no trial is currently underway.
Ongoing European studies
A randomized phase II trial (DESMOPAZ) evaluating pazopanib
versus methotrexate plus vinblastine in 94 patients is ongoing in
France (NCT01876082). In Italy, a phase II study evaluating tore-
mifene in DF is recruiting (NCT02353429). In Spain, there is an
ongoing study with nab-paclitaxel in DF and Ewing sarcomas.
Another trial is evaluating the mTOR inhibitor sirolimus in chil-
dren and young adults with desmoid-type fibromatosis
(NCT01265030).
In general, it is reasonable to employ the less toxic before the
more toxic therapies in a stepwise fashion. Due to the lack of
randomized data, we are still not in the situation to propose a de-
finitive sequence of the existing systemic treatment options. Out
of the variety of possible systemic treatment options, one can be
chosen taking into account the dynamic growth of the tumor and
the urgency of treatment, the expected response rate, the planned
treatment duration and the toxicity of the administered drug.
Note, that often long-term treatment periods are necessary with
some TKIs to achieve tumor shrinkage and control tumor
growth. Comparative and randomized studies are highly encour-
aged in the medical treatment setting to gain more evidence-
based data which could help to guide us through the treatment
plan. Many drugs described above are not licensed for DF and,
therefore, not available or reimbursed in most European coun-
tries. Efforts are needed to make tyrosine kinase or gamma-
secretase inhibitors accessible and involving patient advocacy
groups such as SPAEN is essential in pushing that forward.
Main challenges for DF patients—the
patients’ perspective
DF diagnosis is often hampered by misdiagnosis resulting in a
long timeframe from first symptoms until correct diagnosis.
Patients are often relieved to get the diagnosis of a ‘benign dis-
ease’ underestimating the possible aggressive course. Uncertainty
in diagnosis, treatment and possible recurrence often requires
psychologic support. Considering the peak age of 35 years, pa-
tients often feel they are losing their independence just at the time
they are starting to gain it.
Comprehensive programs especially for adolescents are needed
including physical, psychologic and social support. Follow-up
does not follow patterns of more common cancer types, being
highly individualized according to physical, psychologic and so-
cial aspects. There is room for a symptom-driven follow-up strat-
egy and a strict recommendation on follow-up procedures
cannot be given. After 1 year of follow-up DF patients should not
be discouraged to become pregnant. There may be a risk of tumor
development during or after pregnancy. However, if the tumor
has been stable before pregnancy, it is most likely to regress again
afterwards [43].
Experts may recommend getting in touch with other patients
to relieve the feeling of isolation and to help to restore a sense of
normality. National and international patient advocacy groups
such as SPAEN can be of substantial support here (http://www.
sarcoma-patients.eu/en/).
Consensus algorithm
A multidisciplinary discussion in soft tissue tumor boards is ne-
cessary to propose a personalized management; furthermore, a
discussion with the patient is also necessary for tailoring this pro-
posal to its objectives given the natural course of the disease.
Patient advocacy groups are helpful to reinforce the explanations
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given by health professionals and avoid some misunderstanding
especially about the wait and see policy. Second opinion by an ex-
pert pathologist as well as clinical management by an expert team
is highly recommended (Figure 4).
There is clear consensus that a conservative watch and wait strat-
egy should be the front-line approach to newly diagnosed patients,
irrespective of existing pain or other clinical symptoms, offering a
way to understand the behavior of the disease and tailor next treat-
ment steps. The time interval for a watch and wait approach could
be 1–2 years and patients should be closely followed, preferably
using contrast enhanced MRI. The first clinical and/or radiologic
re-evaluation should be done within 8–12 weeks, then every
3 months in the first year, then 6 monthly up to the fifth year, and
yearly thereafter. In the case of progression, alternative treatment
options should be discussed. To define the cut-off for an active
treatment, different factors have to be taken into account such as
initial tumor size, growth rate, anatomical localization, risk to
organs/nerves etc., compression and worsening of function. In
most cases, the strategy is switched to a definitive treatment in the
case of an objective tumor size progression in multiple (e.g. three)
consecutive images and further steps should be tailored as
described in the depicted algorithm (Figure 4).
In the case of a progressing DF localized at the abdominal wall,
hormonal therapy might be an option. A more definitive strategy,
of course, would be surgical resection or radiotherapy.
For intraabdominal DF, it was clearly agreed that surgery re-
mains the main treatment in the case of progression, if the tumor
is operable. For retroperitoneal or pelvic DF medical therapy
should be the first therapeutic option. In the case of further
progression or relapse, medical therapy, surgery or radiotherapy
would be an option with a tendency toward surgery if the tumor
is resectable with preservation of function.
For DF of the extremities, girdles or chest wall the decision for
the type of the initial treatment should be guided by the expected
postoperative functional impairment or morbidity. As this can be
highly subjective, of course, postoperative consequences should
be clearly discussed with the patient. If the lesion is not involving
major vessels or nerves an observation strategy should be contin-
ued. If the lesion threatens to involve major vessels or nerves, sur-
gical resection should not necessarily be considered the first
option; the alternative would be medical therapy or radiotherapy
alone. Other alternatives for a limb tumor include ILP which can
be considered for tumors located in the extremities, especially ad-
visable in multifocal disease and tumors of the hand or foot. No
resection of the remnant tumor is usually proposed. In the case of
further progression or relapse, definitive surgery could then be
proposed. In the case of positive surgical margins and critical
situations, adjuvant radiotherapy may be considered.
For critical anatomical localizations such as head and neck and
intrathoracic sites medical therapy is generally considered the
first line option. However, in selected conditions (elder age, pa-
tient intolerance/preference, comorbidities, lesion growing rap-
idly and threatening vital organs etc.) radiotherapy is a
reasonable and effective first line alternative. In the case of further
progression or relapse, radiotherapy should be discussed in these
highly radiosensitive structures. If surgery is considered, add-
itional radiotherapy should always be considered to minimize the
risk of local relapse.
Diagnosis (core needle biopsy)
Front-line approach: watch & wait (1-2 years)
In case of progression
Abdominal wall
S S*
S*/RT or
both
S*HT MT
MT (or RT) MT ILP
Investigational treatments,...
Abbreviations: HT: hormonal therapy; S: surgery; S*: surgery is an option if morbidity is limited; MT: medical therapy; RT: radiotherapy; ILP:
isolated limb perfusion
RT RT or S*+RT
MT
MT
MT
Intra-
abdominal
Retroperito-
neal/pelvic
Extremity/girdles/
chest wall
Head & neck/
intrathoracic 
In case of stabilization or
regression: watch & wait
(consider-if clinically possible-to wait until 3 subsequent progression)
Figure 4. Consensus algorithm.
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Disclaimer
These recommendations reflect the state of knowledge, current
at the time of publication, on effective and appropriately vali-
dated data, as well as clinical consensus judgments when know-
ledge is lacking. The inevitable changes in the state of scientific
information and technology mandate that periodic review,
updating and revisions will be needed. Expert opinions users al-
ways are urged to seek out newer information that might impact
the diagnostic and treatment recommendations contained
within. These expert opinions do not apply to all patients, and
must be adapted and tailored to each individual patient. Proper
use, adaptation modifications or decisions to disregard these or
other guidelines, in whole or in part, are entirely the responsibil-
ity of the clinician who uses the expert opinions. Ultimately,
healthcare professionals must make their own treatment deci-
sions about care on a case-by-case basis, after consultation with
their patients, using their clinical judgment, knowledge and ex-
pertise. An expert opinion is not intended to take the place of
physician or a researcher judgment in diagnosing and treatment
of particular patients or in conducting specific research activ-
ities. Expert opinions may not be complete or accurate. The
EORTC and members of their boards, officers and employees
disclaim all liability for the accuracy or completeness of an ex-
pert opinion, and disclaim all warranties, express or implied to
their incorrect use.
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